A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer

BACKGROUND: Cabozantinib can enhance the effect of abiraterone in preclinical prostate cancer models. This study aimed to define the recommended phase 2 dose (RP2D) and preliminary efficacy of abiraterone+cabozantinib in mCRPC. METHODS: Patients with progressive mCRPC with 0–2 prior chemotherapy reg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate
Autors principals: Choudhury, Atish D., Gray, Kathryn P., Supko, Jeffrey G., Harshman, Lauren C., Taplin, Mary-Ellen, Pace, Amanda Fredericks, Farina, Matthew, Zukotynski, Katherine A., Bernard, Brandon, Kantoff, Philip W., Pomerantz, Mark, Sweeney, Christopher
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286224/
https://ncbi.nlm.nih.gov/pubmed/29882250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23662
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars